The agreement covers both an mRNA and a protein-based technology, its documentation and patents within the field of HSV-2. By entering this agreement, all activities related to the development, manufacture and commercialization until an out-licensing agreement with a third party is signed, will be managed and financed by
The proceeds from any future out-licensing or granting of rights to third parties shall be shared between
- I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec, says CEO
Herpes Simplex Virus Type 2 is a sexually transmitted disease that affects about half a billion people worldwide according to WHO. Implications that follow include painful genital blisters and/or ulcers, depression resulting from the negative impact on quality of life and sexual relationships, increased risk of HIV, neurological disabilities due to neonatal herpes and in rare cases, encephalitis. Presently treated mainly by antivirals, no effective therapeutic vaccine is available on the market today.
- We are very content to have engaged
Redbiotec is a private biotech company located near
Immediate action points following the signing of this agreement include;
- Planning the forthcoming development, including preclinical and clinical studies, documentation, patents and business development along with active marketing.
- Deciding which technology to pursue - the mRNA or protein-based vaccine candidate.
- Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.
Read more about our development process, how we bridge the gap between innovation and market: https://www.eurocine-vaccines.com/bridging-the-gap/
This information is such information that
Hans Arwidsson, Ph.D., MBA
CEO of
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
Listed at
https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-expands-its-portfolio-with-a-therapeutic-hsv-2-vaccine-candidate,c3585336
https://mb.cision.com/Main/11552/3585336/1592747.pdf
https://news.cision.com/eurocine-vaccines/i/centrifug,c3060763
(c) 2022 Cision. All rights reserved., source